Clinical Trials

Colonic Neoplasms, Colorectal Neoplasms

NCT04511039 2026-05-04

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Colorectal Neoplasms

NCT05198934 2026-04-27

CodeBreak300

160 enrolled 1 FDA

Colorectal Neoplasms

NCT04868773 2026-04-24

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Phase 1 Completed

15 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 3 Not yet recruiting

110 enrolled

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms

NCT07525206 2026-04-13

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

700 enrolled

Colorectal Neoplasms

NCT05854498 2026-04-02

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

50 enrolled

Colorectal Neoplasms

NCT06607458 2026-03-13

DEL-LIVER

90 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT03223779 2026-03-12

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

Phase 1/2 Completed

52 enrolled

Colorectal Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Phase 2 Completed

42 enrolled 12 charts

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Phase 2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Colorectal Neoplasms

NCT04457297 2026-01-21

ALTAIR

243 enrolled 13 charts

Phase 2 Active not recruiting

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03844620 2026-01-09

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

94 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05839951 2025-11-12

STAR-T

Completed

818 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT05029882 2025-10-29

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

520 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

57 enrolled

Colorectal Neoplasms

NCT06614192 2025-08-26

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Phase 3 Recruiting

460 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT04166604 2025-08-19

LONGBOARD

176 enrolled

Neutropenia, Colorectal Neoplasms

NCT05328908 2025-08-13

RELATIVITY-123

Phase 3 Terminated

770 enrolled

Phase 2 Not yet recruiting

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Neutropenia, Colorectal Neoplasms

NCT04450836 2025-03-30

SOREGATT

Phase 2 Terminated

234 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT06882915 2025-03-19

Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study

20 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

64 enrolled

Phase 2 Active not recruiting

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

50 enrolled